Key result
Cardiomyocyte PKN2 deficiency leads to severe congenital cardiac defects and heart failure, while PKN2 haploinsufficiency attenuates cardiac hypertrophy and fibrosis in response to angiotensin II-induced hypertension.
Why the study?
The role of PKN2 in contractile cardiomyocytes during development and its role in the adult heart remained to be fully established.
Does PKN2 deficiency alter cardiac development and angiotensin II-induced cardiac hypertrophy in mice?
Does PKN2 deficiency alter cardiac development and angiotensin II-induced cardiac hypertrophy in mice?
PKN2 is essential for embryonic heart development and mediates cardiac hypertrophy and fibrosis in response to angiotensin II-induced hypertension, suggesting a potential therapeutic target for heart disease.
Cardiomyocyte PKN2 supports compact myocardium formation and stress-induced hypertrophy in mice; hypothesis-generating for human cardiomyopathy roles.
Background The protein kinase PKN2 is required for embryonic development, and PKN2 knockout mice die as a result of failure in expansion of mesoderm tissues, cardiac development and neural tube closure. In the adult, cardiomyocyte PKN2 and PKN1 (in combination) are required for cardiac adaptation to pressure-overload. The role of PKN2 in contractile cardiomyocytes during development and its role in the adult heart remain to be fully established. Methods We used mice with cardiomyocyte-directed knockout of PKN2 or global PKN2 haploinsufficiency. Cardiac function and dimensions were assessed with high resolution episcopic microscopy, MRI, micro-CT and echocardiography. Biochemical and histological changes were assessed. Results Cardiomyocyte-directed PKN2 knockout embryos displayed striking abnormalities in the compact myocardium, with frequent myocardial clefts and diverticula, ventricular septal defects and abnormal heart shape. The sub-Mendelian homozygous knockout survivors developed cardiac failure. RNASeq data showed upregulation of PKN2 in patients with dilated cardiomyopathy, suggesting an involvement in adult heart disease. Given the rarity of homozygous survivors with cardiomyocyte-specific deletion of PKN2, this was explored using mice with constitutive heterozygous PKN2 knockout. Cardiac hypertrophy resulting from hypertension induced by angiotensin II was reduced in haploinsufficient PKN2 mice relative to wild-type littermates, with suppression of cardiomyocyte hypertrophy and cardiac fibrosis. Conclusions Cardiomyocyte PKN2 is essential for heart development and formation of compact myocardium, and is also required for cardiac hypertrophy in hypertension. Thus, PKN signalling may offer therapeutic options for managing congenital and adult heart diseases.
No takes yet. Share an insight, caveat, or question.
Marshall et al. (2022) studied Congenital cardiomyopathy and cardiac hypertrophy. PKN2 deficiency (knockout or haploinsufficiency) vs. Wild-type littermates was evaluated on Cardiac development and response to AngII-induced hypertension. Cardiomyocyte PKN2 deficiency leads to severe congenital cardiac defects and heart failure, while PKN2 haploinsufficiency attenuates cardiac hypertrophy and fibrosis in response to angiotensin II-induced hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: